Inovio Pharmaceuticals Inc. (NASDAQ:INO) shares are trading higher Thursday after the company announced it received regulatory authorization from Brazil’s ANVISA to initiate the global Phase 3 segment of its Phase 2/3 trial for INO-4800. Inovio Pharmaceuticals stock was up 9.3% at $9.22 at last check.
